Grading of Prostate Cancer: a Work in Progress
Overview
Pathology
Affiliations
Grading of prostate cancer has evolved substantially over time, not least because of major changes in diagnostic approach and concomitant shifts from late- to early-stage detection since the adoption of PSA testing from the late 1980s. After the conception of the architecture-based nine-tier Gleason grading system more than 50 years ago, several changes were made in order to increase its prognostic impact, to reduce interobserver variation and to improve concordance between prostate needle biopsy and radical prostatectomy grading. This eventually resulted in the current five-tier grading system, with a much more detailed description of the individual architectural patterns constituting the remaining three Gleason patterns (i.e. grades 3-5). Nevertheless, there is room for improvement. For instance, distinction of common grade 4 subpatterns such as ill-formed and fused glands from the grade 3 pattern is challenging, blurring the division between low-risk patients who could be eligible for deferred therapy and those who need curative therapy. The last few years have witnessed the publication of several studies on the prognostic impact of individual architectural subpatterns showing that, in particular, the cribriform pattern exceeded the prognostic impact of other grade 4 subpatterns. This review provides an overview of the changes in prostate cancer grading over time and provides a thorough description of the various Gleason subpatterns, the current evidence of their prognostic impact and areas of contention. Potential practical ways for improvements of the current grading system are also put forward.
Histopathological evaluation and grading for prostate cancer: current issues and crucial aspects.
Agosti V, Munari E Asian J Androl. 2024; 26(6):575-581.
PMID: 39254403 PMC: 11614181. DOI: 10.4103/aja202440.
Cribriform versus Intraductal: How to Determine the Difference.
Comperat E, Klager J, Rioux-Leclercq N, Oszwald A, Wasinger G Cancers (Basel). 2024; 16(11).
PMID: 38893122 PMC: 11171388. DOI: 10.3390/cancers16112002.
van Wyk A, Lal P, Ogunbiyi J, Kyokunda L, Hobenu F, Dial C JCO Glob Oncol. 2024; 10:e2300403.
PMID: 38870437 PMC: 11191871. DOI: 10.1200/GO.23.00403.
The Current Therapeutic Landscape for Metastatic Prostate Cancer.
Bernal A, Bechler A, Mohan K, Rizzino A, Mathew G Pharmaceuticals (Basel). 2024; 17(3).
PMID: 38543137 PMC: 10974045. DOI: 10.3390/ph17030351.
Das S, Luu M, Terris M, Klaassen Z, Kane C, Amling C Urol Oncol. 2024; 42(6):175.e1-175.e8.
PMID: 38490923 PMC: 11370885. DOI: 10.1016/j.urolonc.2024.02.010.